Ethnic variability in the plasma exposures of oatp1b1 substrates such as HMG-CoA reductase inhibitors: A kinetic consideration of its mechanism

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 1, 2013, Pages 37-51

  Tomita, Y ^a   Maeda, K ^b   Sugiyama, Y ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CANDESARTAN HEXETIL; CERIVASTATIN; CYCLOSPORIN A; GEMFIBROZIL; GEMFIBROZIL GLUCURONIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; OLMESARTAN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1 B1; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; SARTAN DERIVATIVE; SIMVASTATIN; TELMISARTAN; TEMOCAPRIL; UNCLASSIFIED DRUG; VALSARTAN;

AREA UNDER THE CURVE; CAUCASIAN; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; JAPANESE; KIDNEY CLEARANCE; LIVER CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 84879388463     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.221     Document Type: Review

References (75)

1. Ma, J.D., Nafziger, A.N. & Bertino, J.S. Jr. Genetic polymorphisms of cytochrome P450 enzymes and the efect on interindividual, pharmacokinetic variability in extensive metabolizers. J. Clin. Pharmacol. 44, 447-456 (2004).
2. Maeda, K. & Sugiyama, Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 23, 223-235 (2008).
3. Beierle, I., Meibohm, B. & Derendorf, H. Gender diferences in pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol. Ther. 37, 529-547 (1999).
4. Chen, M.L. Ethnic or racial diferences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 45, 957-964 (2006).
5. Shitara, Y. & Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual diferences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71-105 (2006).
6. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011).
7. Yoshida, K., Maeda, K. & Sugiyama, Y. Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin. Pharmacol. Ther. 91, 1053-1064 (2012).
8. Kalliokoski, A. & Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705 (2009).
9. Hirano, M., Maeda, K., Shitara, Y. & Sugiyama, Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311, 139-146 (2004).
10. Kitamura, S., Maeda, K., Wang, Y. & Sugiyama, Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36, 2014-2023 (2008).
11. Yamada, A. et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab. Dispos. 35, 2166-2176 (2007).
12. Ishiguro, N. et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos. 34, 1109-1115 (2006).
13. Yamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z. & Sugiyama, Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34, 1247-1254 (2006).
14. Watanabe, T., Kusuhara, H. & Sugiyama, Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J. Pharmacokinet. Pharmacodyn. 37, 575-590 (2010).
15. Shitara, Y., Itoh, T., Sato, H., Li, A.P. & Sugiyama, Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304, 610-616 (2003).
16. Lau, Y.Y., Huang, Y., Frassetto, L. & Benet, L.Z. Efect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007).
17. Link, E. et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
18. Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side efects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009).
19. Donnelly, L.A. et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89, 210-216 (2011).
20. Nishizato, Y. et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
21. Niemi, M. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14, 429-440 (2004).
22. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Diferent efects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733 (2007).
23. Singhvi, S.M., Pan, H.Y., Morrison, R.A. & Willard, D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29, 239-243 (1990).
24. Martin, P.D. et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 25, 2822-2835 (2003).
25. Ho, R.H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
26. Niemi, M. et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics 16, 801-808 (2006).
27. Zhang, W. et al. Role of BCRP 421CA polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373, 99-103 (2006).
28. Ieiri, I. et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82, 541-547 (2007).
29. Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly afects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86, 197-203 (2009).
30. Shitara, Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfbrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfbrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
31. Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly afects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006).
32. Maeda, K. et al. Efects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79, 427-439 (2006).
33. Mwinyi, J., Johne, A., Bauer, S., Roots, I. & Gerlof, T. Evidence for inverse efects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004).
34. Ho, R.H. et al. Efect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet. Genomics 17, 647-656 (2007).
35. Chung, J.Y. et al. Efect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78, 342-350 (2005).
36. Choi, J.H., Lee, M.G., Cho, J.Y., Lee, J.E., Kim, K.H. & Park, K. Infuence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83, 251-257 (2008).
37. Wen, J. & Xiong, Y. OATP1B1 388AG polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J. Clin. Pharm. Ther. 35, 99-104 (2010).
38. Camenisch, G. & Umehara, K. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientifc and pharmaceutical perspective for assessing drug-drug interactions. Biopharm. Drug Dispos. 33, 179-194 (2012).
39. Ménochet, K., Kenworthy, K.E., Houston, J.B. & Galetin, A. Use of mechanistic modeling to assess interindividual variability and interspecies diferences in active uptake in human and rat hepatocytes. Drug Metab. Dispos. 40, 1744-1756 (2012).
40. Watanabe, T. et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab. Dispos. 38, 215-222 (2010).
41. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652-662 (2009).
42. Martin, P.D., Warwick, M.J., Dane, A.L., Brindley, C. & Short, T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin. Ther. 25, 2553-2563 (2003).
43. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005).
44. Warrington, S., Nagakawa, S. & Hounslow, N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin. Drug Investig. 31, 735-743 (2011).
45. Shugarts, S. & Benet, L.Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 26, 2039-2054 (2009).
46. Li, Z. et al. Efects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica. 39, 788-793 (2009).
47. Poirier, A., Cascais, A.C., Funk, C. & Lavé, T. Prediction of pharmacokinetic profle of valsartan in human based on in vitro uptake transport data. J. Pharmacokinet. Pharmacodyn. 36, 585-611 (2009).
48. Suwannakul, S. et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J. Hum. Genet. 53, 899-904 (2008).
49. Yamada, A. et al. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet. Genomics 21, 523-530 (2011).
50. Nishino, A., Kato, Y., Igarashi, T. & Sugiyama, Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. Drug Metab. Dispos. 28, 1146-1148 (2000).
51. Yoshihara, K., Gao, Y., Shiga, H., Wada, D.R. & Hisaoka, M. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Clin. Pharmacokinet. 44, 1329-1342 (2005).
52. Tatami, S., Yamamura, N., Sarashina, A., Yong, C.L., Igarashi, T. & Tanigawara, Y. Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab. Pharmacokinet. 19, 15-23 (2004).
53. Sunkara, G., Yeh, C., Saylan, M.L., Kawashita, H., Koseki, N. & Fukui, Y. Assessment of ethnic diferences in the pharmacokinetics and pharmacodynamics of valsartan. J. Bioequiv. Availab. 2, 120-124 (2010).
54. Pasanen, M.K., Backman, J.T., Neuvonen, P.J. & Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006).
55. Nozawa, T. et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813 (2002).
56. Zamber, C.P. et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13, 19-28 (2003).
57. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
58. Roberts, M.S. & Rowland, M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14, 227-260 (1986).
59. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H. & Sugiyama, Y. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17, 273-310 (1996).
60. Yamazaki, M., Suzuki, H. & Sugiyama, Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13, 497-513 (1996).
61. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex afect the pharmacokinetics of pravastatin but not fuvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006).
62. Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T. & Sugiyama, Y. Clinical signifcance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in the hepatic clearance and intestinal absorption. Biopharm. Drug Dispos. 34, 45-78 (2013).
63. Poirier, A., Funk, C., Scherrmann, J.M. & Lavé, T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol. Pharm. 6, 1716-1733 (2009).
64. Maeda, K. et al. Identifcation of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin. Pharmacol. Ther. 90, 575-581 (2011).
65. Tirona, R.G. Ethnic diferences in statin disposition. Clin. Pharmacol. Ther. 78, 311-316 (2005).
66. Ji, C., Tschantz, W.R., Pfeifer, N.D., Ullah, M. & Sadagopan, N. Development of a multiplex UPLC-MRM MS method for quantifcation of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. Anal. Chim. Acta 717, 67-76 (2012).
67. Ohtsuki, S. et al. Simultaneous absolute protein quantifcation of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83-92 (2012).
68. Bailey, K.M. et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ. Cardiovasc. Genet. 3, 276-285 (2010).
69. Pan, H.Y. et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br. J. Clin. Pharmacol. 31, 665-670 (1991).
70. Gustavson, L.E. et al. The efects of multiple doses of fenofbrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J. Clin. Pharmacol. 45, 947-953 (2005).
71. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no efect on pravastatin. Clin. Pharmacol. Ther. 66, 118-127 (1999).
72. Kovarik, J.M. et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J. Clin. Pharmacol. 42, 222-228 (2002).
73. Neuvonen, P.J., Kantola, T. & Kivistö, K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63, 332-341 (1998).
74. Azie, N.E., Brater, D.C., Becker, P.A., Jones, D.R. & Hall, S.D. The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. 64, 369-377 (1998).
75. Kantola, T., Backman, J.T., Niemi, M., Kivistö, K.T. & Neuvonen, P.J. Efect of fuconazole on plasma fuvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56, 225-229 (2000). physiology"